Cipla gets USFDA nod for HIV drug

Pharma firm Cipla has got tentative USFDA approval for its abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine.

According to information available on the USFDA website, the tentative approval is for the oral solution of strength 10mg per ml.

The drug is in a class of medications called nucleoside reverse transcriptase inhibitors. It works by stopping the spread of the HIV and hepatitis-B viruses.